The use of cholinesterase inhibitors and the risk of myocardial infarction and death: A nationwide cohort study in subjects with Alzheimer's disease

European Heart Journal

Volumn 34, Issue 33, 2013, Pages 2585-2591

  Nordström, Peter ^a   Religa, Dorota ^b   Wimo, Anders ^b   Winblad, Bengt ^b   Eriksdotter, Maria ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's dementia; Choline esterase inhibitors; Myocardial infarction

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CAUSE OF DEATH; CHOLINESTERASE INHIBITION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REGISTER; RISK ASSESSMENT; RISK REDUCTION; SWEDEN; TREATMENT OUTCOME;

ALZHEIMER'S DEMENTIA; CHOLINE ESTERASE INHIBITORS; MYOCARDIAL INFARCTION;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84883006562     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht182     Document Type: Article

References (32)

1. WHO. The 10 leading causes of death by broad income group. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, WilsonPW,Woo YJ. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-944.
3. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-329.
4. Birks J. Cholinesterase inhibitors for Alzheimer?s disease. Cochrane Database Syst Rev 2006;1:CD005593.
5. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-124. (Pubitemid 38056032)
6. Pollak Y, Gilboa A, Ben-Menachem O, Ben-Hur T, Soreq H, Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol 2005;57:741-745. (Pubitemid 40628864)
7. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer?s disease patients. Exp Gerontol 2005;40:165-171. (Pubitemid 40343007)
8. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and antiinflammatory cytokines. J Neuroimmunol 2004;148:162-171. (Pubitemid 38229569)
9. Folstein MF, Folstein SE, McHugh PR. ?Mini-mental state?. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
10. Religa D, Spangberg K,WimoA, Edlund AK, Winblad B, Eriksdotter-Jonhagen M. Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry. Dement Geriatr Cogn Disord 2012;33:90-95.
11. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. Anational record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001;30(Suppl 1):S30-S34. (Pubitemid 33041209)
12. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer?s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24:20-27. (Pubitemid 46985287)
13. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer?s disease. Donepezil Study Group. Neurology 1998;50:136-145. (Pubitemid 28106032)
14. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer?s disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244. (Pubitemid 29224502)
15. Finucane TE. Getting donepezil into the nursing home. J Am Geriatr Soc 2003;51: 133-134; author reply
16. Seltzer B, Zolnouni P,Nunez M, Goldman R, Kumar D, Ieni J, Richardson S. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004;61:1852-1856. (Pubitemid 39612945)
17. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer?s disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737-744. (Pubitemid 36693421)
18. WimoA, Winblad B, Engedal K, Soininen H, VerheyF,Waldemar G,Wetterholm AL, Mastey V, Haglund A, Zhang R, Miceli R, ChinW, Subbiah P. An economic evaluation of donepezil in mild to moderate Alzheimer?s disease: results of a 1-year, doubleblind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44-54. (Pubitemid 35404261)
19. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer?s disease over a 2-year period. Curr Med Res Opin 2005;21:1317-1327. (Pubitemid 41140736)
20. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer?s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445-1449.
21. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276. (Pubitemid 30416277)
22. Raskind MA, Peskind ER,Wessel T, YuanW. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268. (Pubitemid 30416276)
23. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer?s disease: international randomised controlled trial. BMJ 1999;318:633-638.
24. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-422. (Pubitemid 32217458)
25. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
26. Pavlov VA, Ochani M, Gallowitsch-Puerta M, Ochani K, Huston JM, Czura CJ, Al-Abed Y, Tracey KJ. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 2006;103: 5219-5223.
27. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, Chavan S, Al-Abed Y, Tracey KJ. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 2009; 23:41-45.
28. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009; 265:663-679.
29. Inanaga K, Ichiki T, Miyazaki R, Takeda K, Hashimoto T, Matsuura H, Sunagawa K. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis 2010;213:52-58.
30. Okazaki Y, Zheng C, Li M, Sugimachi M. Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 2010;60:67-74.
31. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med 2009;6:e1000157.
32. Isik AT, Bozoglu E, Yay A, Soysal P, Ateskan U. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer?s disease? Am J Alzheimers Dis Other Demen 2012;27:171-174.